Ketamine sublingual - iX Biopharma

Drug Profile

Ketamine sublingual - iX Biopharma

Alternative Names: Ketamine wafer - iX Biopharma; Wafermine

Latest Information Update: 08 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator iX Biopharma
  • Class Analgesics; Antidepressants; Cyclohexanes; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute pain; Dental pain; Pain

Most Recent Events

  • 17 Jul 2018 iX Biopharma completes a phase II trial in Acute pain in USA (NCT03246971)
  • 08 Feb 2018 iX Biopharma has patent protection for WaferiX drug delivery technology in China, Canada, South Africa, Germany, France, United Kingdom, Italy, Spain, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, Austria, Norway, Denmark, Ireland and Finland
  • 24 Aug 2017 iX Biopharma initiates a phase II trial for Acute pain in USA (NCT03246971)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top